Exosome and Stem Cell Supplier Red Flags: A Compliance Checklist for Doctors and Clinics

The regenerative medicine market has grown fast, faster than regulation has kept up with it. Licensed clinicians now face a crowded field of suppliers selling exosomes and mesenchymal stem cells (MSCs), and the claims attached to those products range from overstated to flatly false. Choosing a supplier isn't just a purchasing decision. It's a professional obligation that touches patient safety, your own liability, and your regulatory standing.

This guide walks through the compliance basics every clinician should understand, the specific questions to ask a supplier before buying, and the warning signs that should end the conversation.

The regulatory baseline: what you actually need to know

Before you evaluate any supplier, it helps to be clear on the regulatory ground you're standing on.

There are currently no FDA-approved exosome products for any therapeutic use. None. The FDA has stated this directly, and has issued public safety alerts and multiple warning letters (to companies including Kimera Labs, Chara Biologics, and Supreme Rejuvenation) making the point explicit. Any supplier who tells you their exosomes are "FDA-approved" is either misinformed or misrepresenting their product, and either way that's a reason to walk away immediately.

Umbilical cord tissue-derived MSCs sit in a related but separate category. They're regulated under 21 CFR Part 1271 as human cells, tissues, and cellular and tissue-based products, commonly shortened to HCT/Ps, not as approved drugs. The baseline manufacturing standard for HCT/Ps is called Current Good Tissue Practice, or cGTP, which is a different regulatory track than Current Good Manufacturing Practice (cGMP), the standard that applies to pharmaceutical drugs and biologics.

A nuance worth understanding, not just repeating: these two frameworks aren't always mutually exclusive in practice. Minimally manipulated HCT/Ps fall squarely under cGTP. But products that are more than minimally manipulated, expanded in culture, or intended for a use other than their original function are regulated more like drugs or biologics, and full cGMP compliance can legitimately apply to them too. Florida's own stem cell statute, for example, requires that source facilities follow "applicable current good manufacturing practices." So the useful question to ask a supplier isn't "cGTP or cGMP, pick one." It's: which framework applies to this specific product, and can you show me the paperwork that proves you're following it?

Florida's stem cell law (SB 1768): a state-level compliance framework

Effective July 1, 2025, Florida Senate Bill 1768 (now Sections 458.3245 and 459.0127 of the Florida Statutes) gives licensed MDs and DOs the ability to administer non-FDA-approved stem cell therapies for orthopedic conditions, wound care, or pain management, as long as specific conditions are met. The law was passed unanimously in both chambers of the Florida legislature. It explicitly bans stem cells sourced from aborted fetal tissue and sets out detailed requirements for sourcing, manufacturing, storage, and documentation.

Key requirements under SB 1768 include:

• Facility registration and accreditation. Stem cells must be collected, processed, and preserved in an FDA-registered facility that also holds accreditation from a recognized body such as the American Association of Tissue Banks (AATB), the Association for the Advancement of Blood and Biotherapies (AABB), or the National Marrow Donor Program (NMDP).
• Cleanroom manufacturing. Cells must be manufactured in an FDA-certified cleanroom using HEPA or ULPA filtration to control particulate contamination.
• Post-thaw viability documentation. Every product lot needs a post-thaw viability report confirming the cells are still viable before they reach a patient.
• Informed consent and advertising disclosures. Physicians must get written informed consent from every patient and include a specific statutory disclosure in any advertising.

If you practice across state lines, AATB accreditation is worth prioritizing specifically, since Florida's statute names it directly as an acceptable accrediting body, and a number of other states that reference tissue-bank standards in their own regenerative medicine rules recognize AATB accreditation the same way.

AATB accreditation: the voluntary gold standard

Accreditation from the American Association of Tissue Banks (AATB) is a voluntary quality standard that goes beyond the FDA's baseline requirements. AATB maintains detailed standards covering donor screening, tissue processing, packaging, labeling, storage, and distribution, and accredited facilities go through regular independent inspections to stay in compliance.

In today's market, the combination of AATB accreditation, FDA tissue establishment registration, cGTP compliance, and a lot-specific Certificate of Analysis is one of the more reliable signals of a legitimate supplier. If a supplier can't produce documentation for these, treat that as a serious warning sign, not a paperwork inconvenience.

cGMP and cGTP for exosome manufacturing, specifically

Some suppliers market their exosomes as "cGMP-grade." A 2025 review published in the journal Biology points out that because the field still lacks fully standardized definitions, it's important to confirm that any product labeled cGMP-grade actually meets FDA expectations for identity, reproducibility, sterility, safety, purity, and potency, rather than just borrowing the label.

Validating each step of manufacturing and keeping batch-to-batch consistency is essential here. Closed-system, automated bioreactor manufacturing is one approach that's been used to produce cGMP-grade extracellular vesicles at scale in a reproducible way.

A short, direct set of questions to bring to any supplier conversation:

"Is your facility registered with the FDA as a tissue establishment? Are your products processed according to cGTP standards under 21 CFR Part 1271? Can you provide a Certificate of Analysis for every lot? And for this specific product, which regulatory framework, cGTP or cGMP, actually applies, and why?"

Nine red flags that should end a supplier conversation

Based on current industry guidance and FDA enforcement patterns, these are the signals that should prompt you to disqualify a supplier, not investigate further:

1. Claims of "FDA-approved" exosomes or MSCs. No such product currently exists.
2. "cGMP" used loosely for tissue-based products with no explanation of which framework actually applies. As above, the honest answer depends on the specific product.
3. No AATB accreditation. For injectable HCT/Ps, this is close to a baseline quality signal at this point.
4. No lot-specific Certificate of Analysis. You should be able to see batch documentation, not just a general brochure.
5. No FDA establishment registration. Tissue establishments are required to register.
6. No physical lab you're allowed to visit. Ask for a tour. A legitimate manufacturer should be comfortable showing you how the product is actually made.
7. No mention of any Investigational New Drug (IND) studies. Ask whether the supplier or its manufacturing partner is involved in any IND-stage research. It's a reasonable signal of long-term regulatory seriousness, not a requirement, but its absence combined with bold therapeutic claims is worth noting.
8. No donor eligibility documentation. Donor screening under 21 CFR Part 1271 Subpart C is required, and the paperwork should exist.
9. No reported endotoxin, sterility, or mycoplasma testing. These are baseline quality control tests, and a supplier who can't produce results for them isn't running proper quality control.

An example of compliant sourcing

RegenOMedix sources stem cell and exosome products manufactured in FDA-registered facilities, using sterile cleanroom environments that follow current Good Manufacturing Practices and carry accreditation from bodies recognized under Florida's statute, including AATB. Its products come with the clinical documentation and compliance credentials expected for licensed medical use, and the company is currently recruiting practitioners for an IRB-sanctioned study evaluating safety, efficacy, and comorbidity outcomes in pain, orthopedic, and wound-healing indications using its Ascellos exosome product.

This is included as one example of what a compliance-forward sourcing approach looks like in practice, not as a substitute for doing your own diligence on any specific supplier, including this one.

Frequently Asked Questions

Is exosome therapy FDA approved? No. There are currently zero FDA-approved exosome products for any therapeutic indication. The FDA has issued public warnings and enforcement letters specifically to correct this misconception in the market.

What's the difference between cGTP and cGMP, and which one should my supplier follow? cGTP (Current Good Tissue Practice, under 21 CFR Part 1271) is the baseline standard for human cell and tissue products. cGMP (Current Good Manufacturing Practice) is the standard for drugs and biologics. Minimally manipulated tissue products generally fall under cGTP; products that are more than minimally manipulated or marketed for a new use may also need to meet cGMP. The right answer depends on the specific product, so ask your supplier directly which framework applies and ask for the documentation to back it up.

Why does AATB accreditation matter if it's voluntary? Because it's currently one of the more rigorous, independently audited quality standards in this space, and several state laws, including Florida's SB 1768, name it directly as an acceptable accrediting body. It's a meaningful signal precisely because it isn't the legal minimum.

What documentation should I ask for before buying from a supplier? At minimum: FDA tissue establishment registration, proof of accreditation (AATB, AABB, or NMDP), a lot-specific Certificate of Analysis, donor eligibility screening records, and endotoxin/sterility/mycoplasma testing results. If any of these is missing, ask why before moving forward.

Does Florida's SB 1768 apply outside of Florida? The law itself only governs physicians licensed in Florida under Chapters 458 and 459. But the sourcing standards it sets, facility registration, accreditation, cleanroom manufacturing, and documentation, are a reasonable benchmark for evaluating suppliers regardless of where you practice.

What are the real risks of using an unvetted supplier? Reported risks with unapproved, poorly sourced stem cell and exosome products include infection, allergic reaction, injection-site problems, and in some cases tumor growth, alongside the separate risk of practicing outside the standard of care and facing licensure or legal exposure.

Key Takeaways

• No exosome product is currently FDA-approved for any therapeutic use. Full stop.
• HCT/Ps like umbilical-cord MSCs are regulated under cGTP (21 CFR Part 1271), though cGMP can also legitimately apply depending on how the product is processed and marketed. Ask which framework applies to your specific product.
• Florida's SB 1768 (effective July 1, 2025) permits licensed MDs and DOs to use non-FDA-approved stem cell therapies for orthopedics, wound care, or pain management, but only under strict sourcing, facility, and documentation requirements.
• AATB accreditation, FDA tissue establishment registration, and lot-specific Certificates of Analysis are the core documents to request from any supplier.
• Nine red flags, from false "FDA-approved" claims to missing sterility testing, should prompt immediate disqualification of a supplier.
• Vetting a supplier is a compliance task with real liability consequences, not a formality.

References

1. "Public Safety Alert Due to Marketing of Unapproved Stem Cell and Exosome Products," U.S. Food and Drug Administration (FDA). Available: https://www.fda.gov/safety/medical-product-safety-information/public-safety-alert-due-marketing-unapproved-stem-cell-and-exosome-products
2. "FDA Warns About Stem Cell Therapies," U.S. Food and Drug Administration (FDA). Available: https://www.fda.gov/consumers/consumer-updates/fda-warns-about-stem-cell-therapies
3. "Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps)," U.S. Food and Drug Administration (FDA), Aug. 2023. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/current-good-tissue-practice-cgtp-and-additional-requirements-manufacturers-human-cells-tissues-and
4. "Senate Bill 1768 (2025), Stem Cell Therapy," The Florida Senate, 2025. Available: https://www.flsenate.gov/Session/Bill/2025/1768
5. "New Florida Law Attempts to Provide Leeway for Certain Stem Cell Treatments," Holland & Knight, Aug. 2025. Available: https://www.hklaw.com/en/insights/publications/2025/08/new-florida-law-attempts-to-provide-leeway-for-certain-stem-cell
6. "Florida Stem Cell Law (SB 1768) Updates and Insights," RegenOMedix, 2025. Available: https://regenomedix.com/florida-stem-cell-law/
7. "FDA Warning Letters on Exosome Products: Regulatory Classification, Enforcement Trends, and Criminal Risks," Armstrong Brady Lyons, Apr. 2026. Available: https://www.armstrongbradylyons.com/library/fda-warning-letters-exosome-product
8. "Kimera Labs, Inc., Warning Letter," U.S. Food and Drug Administration (FDA), Sep. 2023. Available: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/kimera-labs-inc-649343-09012023
9. "Association for Advancing Tissue and Biologics (AATB), Institutional Accreditation," AATB. Available: https://www.aatb.org/
10. E. F. Wiest and A. C. Zubair, "Generation of Current Good Manufacturing Practices-Grade Mesenchymal Stromal Cell-Derived Extracellular Vesicles Using Automated Bioreactors," Biology, vol. 14, no. 3, p. 313, Mar. 2025. doi: 10.3390/biology14030313. Available: https://pubmed.ncbi.nlm.nih.gov/40136569/
11. "A Clinical Study on Safety and Effectiveness of Mesenchymal Stem Cell Exosomes for the Treatment of COVID-19," ClinicalTrials.gov, NCT05787288. Available: https://clinicaltrials.gov/study/NCT05787288

This article is intended for general educational and informational purposes only. There are currently no FDA-approved exosome products in the United States. Nothing here constitutes legal advice or a therapeutic endorsement. Healthcare professionals should consult qualified legal and regulatory counsel for guidance specific to their practice and jurisdiction.